Armed Forces personnel will benefit from a £50 million investment in Defence Medical capabilities over the next four years as part of the Government’s Defence Investment Plan (DIP) published on Tuesday 30 June.
The investment will help deliver modern, deployable and life-saving medical capabilities designed to support personnel operating in the most demanding of environments wherever they are deployed.
The new funding package will focus on four key areas
- £20 million for Tactical Combat Casualty Care equipment, providing Armed Forces personnel with the latest battlefield medical kits designed to reduce preventable deaths and improve care at the point of injury.
- £10 million for dried blood products, supporting the Blood Far Forward programme and enabling life-saving blood transfusion care closer to the battlefield by reducing reliance on refrigeration.
- £10 million for Tranexamic Acid (TXA) autoinjectors, allowing blood-clotting medication to be administered rapidly on the battlefield and improving survival from severe blood loss.
- £10 million for field hospital equipment, strengthening deployable medical capability and ensuring Defence can deliver high-quality healthcare during operations at scale.
Chief of Defence Medical, Air Marshal Clare Walton, said
The Defence Investment Plan recognises that the health and operational medical care of service personnel is fundamental to military effectiveness and future fighting power.
By investing in advanced trauma care, blood products and modern medical equipment, we are strengthening operational readiness, improving survivability and ensuring Defence Medical remains ready to save lives in the most challenging environments.
Head of Medical Operations and Capability, Brigadier Chris Wright, added
This is great news, we are getting the modernisation programs that are vital for the Transition to War, optimising and modernising our deployed capabilities.
This investment will deliver practical enhancements to the capabilities our people rely on from advanced casualty care and battlefield blood products to modernised field hospital equipment.
The investment comes as Defence continues preparations for Transition to War, ensuring medical support keeps pace with the evolving demands of modern warfare.
Recent conflicts have reinforced the critical importance of advanced combat medical capabilities and rapid casualty care in sustaining operational effectiveness.
The £50 million investment also sits within a much broader commitment to fund Defence Medical capability already in place before the Defence Investment Plan was published.
The Defence Investment Plan also outlined the intension to invest at least £3 billion between 2030 and 2035 in Joint Support Enablement and Defence Medical capabilities to support continued advances in combat medicine, protection against chemical, biological, radiological and nuclear threats, and the systems required to sustain the Integrated Force on future operations.